DE60023923D1 - Modulatoren der protein tyrosin phosphatase (ptpases) - Google Patents

Modulatoren der protein tyrosin phosphatase (ptpases)

Info

Publication number
DE60023923D1
DE60023923D1 DE60023923T DE60023923T DE60023923D1 DE 60023923 D1 DE60023923 D1 DE 60023923D1 DE 60023923 T DE60023923 T DE 60023923T DE 60023923 T DE60023923 T DE 60023923T DE 60023923 D1 DE60023923 D1 DE 60023923D1
Authority
DE
Germany
Prior art keywords
sub
ptpases
protein tyrosine
modulators
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023923T
Other languages
English (en)
Inventor
Sune Andersen
Kruse Hansen
Jesper Lau
Ller Peter M
Hvilsted Olsen
Urban Axe
Yu Ge
Dale Holsworth
Kevin Jones
Milburn Judge
Charles Ripka
Zvi Shapira
Teruyuki Uyeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Ontogen Corp
Original Assignee
Novo Nordisk AS
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Ontogen Corp filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE60023923D1 publication Critical patent/DE60023923D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
DE60023923T 1999-09-10 2000-09-11 Modulatoren der protein tyrosin phosphatase (ptpases) Expired - Lifetime DE60023923D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901278 1999-09-10
PCT/DK2000/000503 WO2001019831A1 (en) 1999-09-10 2000-09-11 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Publications (1)

Publication Number Publication Date
DE60023923D1 true DE60023923D1 (de) 2005-12-15

Family

ID=8103050

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023923T Expired - Lifetime DE60023923D1 (de) 1999-09-10 2000-09-11 Modulatoren der protein tyrosin phosphatase (ptpases)

Country Status (7)

Country Link
US (1) US7019026B1 (de)
EP (1) EP1214325B1 (de)
JP (1) JP2003509430A (de)
AT (1) ATE309250T1 (de)
AU (1) AU6985300A (de)
DE (1) DE60023923D1 (de)
WO (1) WO2001019831A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214060A2 (de) * 1999-09-10 2002-06-19 Novo Nordisk A/S Verfahren zur hemmung von tyrosinphophatase 1b und/oder t-zellenprotein-tyronsinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 4
US20040176324A1 (en) * 2000-09-19 2004-09-09 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US6613903B2 (en) 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
EP1301516B1 (de) * 2000-07-07 2006-03-22 Novo Nordisk A/S Modulatoren von protein tyrosin phosphatasen (ptpasen)
US6972340B2 (en) 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
WO2002100397A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
ES2310622T3 (es) 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
AU2007229370B2 (en) * 2002-04-03 2010-06-17 Novartis Ag 5-substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as PTPase 1B inhibitors
ATE534637T1 (de) 2002-04-03 2011-12-15 Novartis Ag 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
CA2572750A1 (en) * 2003-09-10 2005-03-17 Anil Koul Heterobicyclic compounds as pharmaceutically active agents
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
TW200602337A (en) 2004-02-25 2006-01-16 Wyeth Corp Inhibitors of protein tyrosine phosphatase 1B
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101163690A (zh) * 2005-04-20 2008-04-16 默克公司 苯并噻吩异羟肟酸衍生物
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2985271A1 (en) 2007-09-06 2009-03-12 Ohr Pharmaceutical, Inc. A method for treating diabetes
EP2308877B1 (de) 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-on-derivate
CN102762575B (zh) 2009-12-04 2015-04-15 桑诺维恩药品公司 多环化合物及其使用方法
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
CN102199157B (zh) * 2011-03-17 2013-04-17 鲁东大学 一种含溴的苯并吡喃类化合物及其制备和应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6165843B2 (ja) 2012-04-20 2017-07-19 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
KR101957178B1 (ko) * 2014-04-28 2019-03-12 지앙수 카니온 파마수티컬 씨오., 엘티디. 항엔테로바이러스71 티아디아졸리딘 유도체
CN107325075B (zh) * 2016-04-29 2020-07-28 正大天晴药业集团股份有限公司 一种泊马度胺的制备方法
EA201990399A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения, композиции и их применение
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
EA202090414A1 (ru) 2017-08-02 2020-05-28 Суновион Фармасьютикалз Инк. Соединения и их применение
CA3091292A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CN110054993B (zh) * 2019-04-04 2021-02-26 筑迹(深圳)创新健康科技有限公司 一种长寿命有机硅聚合物抗菌液及其制备方法、抗菌涂层的制备方法
MX2022012833A (es) 2020-04-14 2022-11-07 Sunovion Pharmaceuticals Inc (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953468A (en) 1974-03-15 1976-04-27 The Upjohn Company 3-Cyano thiophen-2-yl oxamic acid and derivatives
GB1583679A (en) 1977-10-11 1981-01-28 Bristol Myers Co Thieno (2,3-d) pyrimidine and other thiophene-derived anti-allergic agents
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
JP2004500308A (ja) * 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1062218A1 (de) * 1998-03-12 2000-12-27 Novo Nordisk A/S Modulatoren der protein-tyrosin-phosphatasen (ptphasen)

Also Published As

Publication number Publication date
US7019026B1 (en) 2006-03-28
EP1214325A1 (de) 2002-06-19
JP2003509430A (ja) 2003-03-11
EP1214325B1 (de) 2005-11-09
ATE309250T1 (de) 2005-11-15
WO2001019831A1 (en) 2001-03-22
AU6985300A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
DE60023923D1 (de) Modulatoren der protein tyrosin phosphatase (ptpases)
ATE329920T1 (de) Modulatoren der protein tyrosin phosphatase (ptpases)
ATE321052T1 (de) Modulatoren von protein tyrosin phosphatasen (ptpasen)
BR9913532A (pt) Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
WO2001017516A3 (en) Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
ATE308546T1 (de) Modulatoren der protein tyrosin phosphatase (ptpases)
GB0213612D0 (en) Organic compounds
ATE396993T1 (de) Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
BR0111451A (pt) Inibidores de serina protease
ATE167221T1 (de) Herstellung von bitumen/polymerzusammensetzungen und ihre verwendung
ATE402188T1 (de) Bindungsproteine als biosensoren
TR199900920T2 (xx) Nafthiridin t�revleri.
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
AU8023898A (en) Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
ATE355284T1 (de) Inhibitoren von serinproteasen
BR9916272A (pt) 4 e 5-alquiniloxindóis e 4 e 5-alqueniloxindóis
DE69628171D1 (de) Mischung zur verbesserung der adhäsion von elastomeren auf polymerzusammensetzungen
PT1267869E (pt) Antogonistas de receptor de glutamato metabotropico para o tratamento de tolerancia e de dependencia
DE60103856D1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
SE9903290D0 (sv) Novel compounds
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
BR9814188A (pt) "agonistas de 5-ht1f"
DK0977495T3 (da) Sammensætning indeholdende pektinmethylesterase og to substrater
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao

Legal Events

Date Code Title Description
8332 No legal effect for de